Outcome of philadelphia chromosome-positive adult acute lymphoblastic leukemia

Stefan Faderl, Hagop M. Kantarjian, Deborah A. Thomas, Jorge Cortes, Francis Giles, Sherry Pierce, Maher Albitar, Zeev Estrov

Research output: Contribution to journalArticle

Abstract

Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) represents the most common cytogenetic abnormality in adult ALL. It is found in 15% to 30% of patients, and its incidence increases with age. As in children, prognosis in Ph-positive adult ALL is poor. No therapeutic approach has had substantial impact on its unfavorable course. We analyzed the characteristics and outcome of newly diagnosed adults with Ph-positive ALL treated at the M.D. Anderson Cancer Center between 1980 and 1997. The diagnosis of patients was based on typical morphological and immunophenotypic criteria of marrow aspirate and biopsy specimens. Cytogenetic and molecular studies were also performed. A total of 67 patients were included in this study. From 1980 until 1991, 38 patients with Ph-positive ALL were treated with vincristine, Adriamycin, and dexamethasone (VAD), or with acute myeloid leukemia (AML)-like induction protocols. Since 1992 a total of 29 patients received induction therapy with an intensified treatment protocol, called 'hyper-CVAD' The outcome of patients treated with standard and intensified treatment regimens was compared and results of our institution contrasted with data obtained from other centers. Ph-positive ALL was present in 67 of 498 patients with newly diagnosed ALL (13%). Patients with Ph-positive. ALL had a higher median age (44 versus 34, P = 0.007), higher median white blood cell (WBC) counts at presentation (25 versus 8: P = 0.0002), and higher peripheral median percentage of blast counts (63 versus 40, P = 0.023). FAB subtype L2 (70% versus 49%, P = 0.001) and CALLA-positive pre-B immunophenotype (75% versus 37%, P < 0.001) predominated among Ph-positive ALL. Myeloid marker coexpression was more frequent in Ph-positive ALL when compared with Ph-negative ALL (52% vs. 27% for CD13, P < 0.001, and 44% vs, 27% for CD33, P = 0.005). Among patients treated with hyper-CVAD, the complete remission (CR) rate was 90% versus 55% (P = 0.002) with pre-hyper-CVAD regimens (VAD and AML-like induction protocols), the median CR duration was 43 weeks versus 32 weeks (P > 0.5), median disease-free survival (DFS) was 42 weeks versus 29 weeks (P = 0.008) and median survival was 66 weeks versus 45 weeks (P > 0.5). Patients with hyper diploid Ph-positive ALL on hyper-CVAD therapy achieved significantly longer CR duration and DFS than hypo- and pseudodiploid cases (59 weeks versus 42 and 31 weeks, P = 0.02 and 0.04, respectively). In contrast, patients treated with regimens prior to hyper-CVAD had significantly shorter CR duration (21 weeks versus 33 and 29 weeks, P = 0.03) and DFS with hyperdiploid karyotypes when compared to pseudodiploid and hypodiploid cases (16 weeks versus 30 and 13 weeks, P = 0.008). In conclusion, our results demonstrate improved response rate and DFS with current intensive regimens (hyper-CVAD) in patients with Ph-positive ALL, but no advantage in overall survival.

Original languageEnglish (US)
Pages (from-to)263-273
Number of pages11
JournalLeukemia and Lymphoma
Volume36
Issue number3-4
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Polyploidy
Survival
Vincristine
Therapeutics
Clinical Protocols
Diploidy
Karyotype
Leukocyte Count
Acute Myeloid Leukemia
Cytogenetics
Chromosome Aberrations
Doxorubicin
Dexamethasone
Bone Marrow

Keywords

  • Acute lymphoblastic leukemia
  • Adult acute leukemias
  • Intensive chemotherapy
  • Philadelphia chromosome
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Faderl, S., Kantarjian, H. M., Thomas, D. A., Cortes, J., Giles, F., Pierce, S., ... Estrov, Z. (2000). Outcome of philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia and Lymphoma, 36(3-4), 263-273. https://doi.org/10.3109/10428190009148847

Outcome of philadelphia chromosome-positive adult acute lymphoblastic leukemia. / Faderl, Stefan; Kantarjian, Hagop M.; Thomas, Deborah A.; Cortes, Jorge; Giles, Francis; Pierce, Sherry; Albitar, Maher; Estrov, Zeev.

In: Leukemia and Lymphoma, Vol. 36, No. 3-4, 01.01.2000, p. 263-273.

Research output: Contribution to journalArticle

Faderl, S, Kantarjian, HM, Thomas, DA, Cortes, J, Giles, F, Pierce, S, Albitar, M & Estrov, Z 2000, 'Outcome of philadelphia chromosome-positive adult acute lymphoblastic leukemia', Leukemia and Lymphoma, vol. 36, no. 3-4, pp. 263-273. https://doi.org/10.3109/10428190009148847
Faderl, Stefan ; Kantarjian, Hagop M. ; Thomas, Deborah A. ; Cortes, Jorge ; Giles, Francis ; Pierce, Sherry ; Albitar, Maher ; Estrov, Zeev. / Outcome of philadelphia chromosome-positive adult acute lymphoblastic leukemia. In: Leukemia and Lymphoma. 2000 ; Vol. 36, No. 3-4. pp. 263-273.
@article{f812cb1c84254991a3d9d459251c849f,
title = "Outcome of philadelphia chromosome-positive adult acute lymphoblastic leukemia",
abstract = "Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) represents the most common cytogenetic abnormality in adult ALL. It is found in 15{\%} to 30{\%} of patients, and its incidence increases with age. As in children, prognosis in Ph-positive adult ALL is poor. No therapeutic approach has had substantial impact on its unfavorable course. We analyzed the characteristics and outcome of newly diagnosed adults with Ph-positive ALL treated at the M.D. Anderson Cancer Center between 1980 and 1997. The diagnosis of patients was based on typical morphological and immunophenotypic criteria of marrow aspirate and biopsy specimens. Cytogenetic and molecular studies were also performed. A total of 67 patients were included in this study. From 1980 until 1991, 38 patients with Ph-positive ALL were treated with vincristine, Adriamycin, and dexamethasone (VAD), or with acute myeloid leukemia (AML)-like induction protocols. Since 1992 a total of 29 patients received induction therapy with an intensified treatment protocol, called 'hyper-CVAD' The outcome of patients treated with standard and intensified treatment regimens was compared and results of our institution contrasted with data obtained from other centers. Ph-positive ALL was present in 67 of 498 patients with newly diagnosed ALL (13{\%}). Patients with Ph-positive. ALL had a higher median age (44 versus 34, P = 0.007), higher median white blood cell (WBC) counts at presentation (25 versus 8: P = 0.0002), and higher peripheral median percentage of blast counts (63 versus 40, P = 0.023). FAB subtype L2 (70{\%} versus 49{\%}, P = 0.001) and CALLA-positive pre-B immunophenotype (75{\%} versus 37{\%}, P < 0.001) predominated among Ph-positive ALL. Myeloid marker coexpression was more frequent in Ph-positive ALL when compared with Ph-negative ALL (52{\%} vs. 27{\%} for CD13, P < 0.001, and 44{\%} vs, 27{\%} for CD33, P = 0.005). Among patients treated with hyper-CVAD, the complete remission (CR) rate was 90{\%} versus 55{\%} (P = 0.002) with pre-hyper-CVAD regimens (VAD and AML-like induction protocols), the median CR duration was 43 weeks versus 32 weeks (P > 0.5), median disease-free survival (DFS) was 42 weeks versus 29 weeks (P = 0.008) and median survival was 66 weeks versus 45 weeks (P > 0.5). Patients with hyper diploid Ph-positive ALL on hyper-CVAD therapy achieved significantly longer CR duration and DFS than hypo- and pseudodiploid cases (59 weeks versus 42 and 31 weeks, P = 0.02 and 0.04, respectively). In contrast, patients treated with regimens prior to hyper-CVAD had significantly shorter CR duration (21 weeks versus 33 and 29 weeks, P = 0.03) and DFS with hyperdiploid karyotypes when compared to pseudodiploid and hypodiploid cases (16 weeks versus 30 and 13 weeks, P = 0.008). In conclusion, our results demonstrate improved response rate and DFS with current intensive regimens (hyper-CVAD) in patients with Ph-positive ALL, but no advantage in overall survival.",
keywords = "Acute lymphoblastic leukemia, Adult acute leukemias, Intensive chemotherapy, Philadelphia chromosome, Survival",
author = "Stefan Faderl and Kantarjian, {Hagop M.} and Thomas, {Deborah A.} and Jorge Cortes and Francis Giles and Sherry Pierce and Maher Albitar and Zeev Estrov",
year = "2000",
month = "1",
day = "1",
doi = "10.3109/10428190009148847",
language = "English (US)",
volume = "36",
pages = "263--273",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - Outcome of philadelphia chromosome-positive adult acute lymphoblastic leukemia

AU - Faderl, Stefan

AU - Kantarjian, Hagop M.

AU - Thomas, Deborah A.

AU - Cortes, Jorge

AU - Giles, Francis

AU - Pierce, Sherry

AU - Albitar, Maher

AU - Estrov, Zeev

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) represents the most common cytogenetic abnormality in adult ALL. It is found in 15% to 30% of patients, and its incidence increases with age. As in children, prognosis in Ph-positive adult ALL is poor. No therapeutic approach has had substantial impact on its unfavorable course. We analyzed the characteristics and outcome of newly diagnosed adults with Ph-positive ALL treated at the M.D. Anderson Cancer Center between 1980 and 1997. The diagnosis of patients was based on typical morphological and immunophenotypic criteria of marrow aspirate and biopsy specimens. Cytogenetic and molecular studies were also performed. A total of 67 patients were included in this study. From 1980 until 1991, 38 patients with Ph-positive ALL were treated with vincristine, Adriamycin, and dexamethasone (VAD), or with acute myeloid leukemia (AML)-like induction protocols. Since 1992 a total of 29 patients received induction therapy with an intensified treatment protocol, called 'hyper-CVAD' The outcome of patients treated with standard and intensified treatment regimens was compared and results of our institution contrasted with data obtained from other centers. Ph-positive ALL was present in 67 of 498 patients with newly diagnosed ALL (13%). Patients with Ph-positive. ALL had a higher median age (44 versus 34, P = 0.007), higher median white blood cell (WBC) counts at presentation (25 versus 8: P = 0.0002), and higher peripheral median percentage of blast counts (63 versus 40, P = 0.023). FAB subtype L2 (70% versus 49%, P = 0.001) and CALLA-positive pre-B immunophenotype (75% versus 37%, P < 0.001) predominated among Ph-positive ALL. Myeloid marker coexpression was more frequent in Ph-positive ALL when compared with Ph-negative ALL (52% vs. 27% for CD13, P < 0.001, and 44% vs, 27% for CD33, P = 0.005). Among patients treated with hyper-CVAD, the complete remission (CR) rate was 90% versus 55% (P = 0.002) with pre-hyper-CVAD regimens (VAD and AML-like induction protocols), the median CR duration was 43 weeks versus 32 weeks (P > 0.5), median disease-free survival (DFS) was 42 weeks versus 29 weeks (P = 0.008) and median survival was 66 weeks versus 45 weeks (P > 0.5). Patients with hyper diploid Ph-positive ALL on hyper-CVAD therapy achieved significantly longer CR duration and DFS than hypo- and pseudodiploid cases (59 weeks versus 42 and 31 weeks, P = 0.02 and 0.04, respectively). In contrast, patients treated with regimens prior to hyper-CVAD had significantly shorter CR duration (21 weeks versus 33 and 29 weeks, P = 0.03) and DFS with hyperdiploid karyotypes when compared to pseudodiploid and hypodiploid cases (16 weeks versus 30 and 13 weeks, P = 0.008). In conclusion, our results demonstrate improved response rate and DFS with current intensive regimens (hyper-CVAD) in patients with Ph-positive ALL, but no advantage in overall survival.

AB - Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) represents the most common cytogenetic abnormality in adult ALL. It is found in 15% to 30% of patients, and its incidence increases with age. As in children, prognosis in Ph-positive adult ALL is poor. No therapeutic approach has had substantial impact on its unfavorable course. We analyzed the characteristics and outcome of newly diagnosed adults with Ph-positive ALL treated at the M.D. Anderson Cancer Center between 1980 and 1997. The diagnosis of patients was based on typical morphological and immunophenotypic criteria of marrow aspirate and biopsy specimens. Cytogenetic and molecular studies were also performed. A total of 67 patients were included in this study. From 1980 until 1991, 38 patients with Ph-positive ALL were treated with vincristine, Adriamycin, and dexamethasone (VAD), or with acute myeloid leukemia (AML)-like induction protocols. Since 1992 a total of 29 patients received induction therapy with an intensified treatment protocol, called 'hyper-CVAD' The outcome of patients treated with standard and intensified treatment regimens was compared and results of our institution contrasted with data obtained from other centers. Ph-positive ALL was present in 67 of 498 patients with newly diagnosed ALL (13%). Patients with Ph-positive. ALL had a higher median age (44 versus 34, P = 0.007), higher median white blood cell (WBC) counts at presentation (25 versus 8: P = 0.0002), and higher peripheral median percentage of blast counts (63 versus 40, P = 0.023). FAB subtype L2 (70% versus 49%, P = 0.001) and CALLA-positive pre-B immunophenotype (75% versus 37%, P < 0.001) predominated among Ph-positive ALL. Myeloid marker coexpression was more frequent in Ph-positive ALL when compared with Ph-negative ALL (52% vs. 27% for CD13, P < 0.001, and 44% vs, 27% for CD33, P = 0.005). Among patients treated with hyper-CVAD, the complete remission (CR) rate was 90% versus 55% (P = 0.002) with pre-hyper-CVAD regimens (VAD and AML-like induction protocols), the median CR duration was 43 weeks versus 32 weeks (P > 0.5), median disease-free survival (DFS) was 42 weeks versus 29 weeks (P = 0.008) and median survival was 66 weeks versus 45 weeks (P > 0.5). Patients with hyper diploid Ph-positive ALL on hyper-CVAD therapy achieved significantly longer CR duration and DFS than hypo- and pseudodiploid cases (59 weeks versus 42 and 31 weeks, P = 0.02 and 0.04, respectively). In contrast, patients treated with regimens prior to hyper-CVAD had significantly shorter CR duration (21 weeks versus 33 and 29 weeks, P = 0.03) and DFS with hyperdiploid karyotypes when compared to pseudodiploid and hypodiploid cases (16 weeks versus 30 and 13 weeks, P = 0.008). In conclusion, our results demonstrate improved response rate and DFS with current intensive regimens (hyper-CVAD) in patients with Ph-positive ALL, but no advantage in overall survival.

KW - Acute lymphoblastic leukemia

KW - Adult acute leukemias

KW - Intensive chemotherapy

KW - Philadelphia chromosome

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0033954540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033954540&partnerID=8YFLogxK

U2 - 10.3109/10428190009148847

DO - 10.3109/10428190009148847

M3 - Article

C2 - 10674898

AN - SCOPUS:0033954540

VL - 36

SP - 263

EP - 273

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3-4

ER -